REPLIGEN CORP Share-based Payment Arrangement, Expense
REPLIGEN CORP (RGEN) reported Share-based Payment Arrangement, Expense of $545.21 thousand for the 3-month period ending 2014-06-30, per its 10-Q filed 2014-08-11.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2014-08-11
- REPLIGEN CORP share-based payment arrangement, expense for the quarter ending 2014-06-30 was $545.21K, a 74.36% increase year-over-year.
- REPLIGEN CORP share-based payment arrangement, expense for the quarter ending 2014-03-31 was $307.43K, a 22.94% increase year-over-year.
- REPLIGEN CORP share-based payment arrangement, expense for the quarter ending 2013-12-31 was $291.47K, a 4.08% increase year-over-year.
- REPLIGEN CORP share-based payment arrangement, expense for the quarter ending 2013-09-30 was $205.77K, a 28.62% decline year-over-year.
- REPLIGEN CORP share-based payment arrangement, expense for fiscal 2013 was $1.06M, a 3.52% increase from fiscal 2012.
- REPLIGEN CORP share-based payment arrangement, expense for fiscal 2012 was $1.02M.
- REPLIGEN CORP share-based payment arrangement, expense for fiscal 2011 was $1.00M.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 3 month as first filed | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|---|
| 2014-06-30 | $545.21K 10-Q · filed 2014-08-11 | $852.64K 10-Q · filed 2014-08-11 | $1.14M derived: sum of 3 quarters · filed 2014-08-11 | $1.35M derived: sum of 4 quarters · filed 2014-08-11 | |
| 2014-03-31 | $307.43K 10-Q · filed 2014-05-09 | $598.89K derived: sum of 2 quarters · filed 2014-05-09 | $804.66K derived: sum of 3 quarters · filed 2014-05-09 | $1.12M derived: sum of 4 quarters · filed 2014-08-11 | |
| 2013-12-31 | $291.47K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-14 | $497.24K derived: sum of 2 quarters · filed 2014-03-14 | $809.93K derived: sum of 3 quarters · filed 2014-08-11 | $1.06M 10-K · filed 2014-03-14 | |
| 2013-09-30 | $205.77K 10-Q · filed 2013-11-08 | $518.46K derived: sum of 2 quarters · filed 2014-08-11 | $768.53K 10-Q · filed 2013-11-08 | $1.05M derived: sum of 4 quarters · filed 2014-08-11 | |
| 2013-06-30 | $312.69K 10-Q · filed 2014-08-11 | $562.76K 10-Q · filed 2014-08-11 | $842.81K derived: sum of 3 quarters · filed 2014-08-11 | $1.13M derived: sum of 4 quarters · filed 2014-08-11 | |
| 2013-03-31 | $250.07K 10-Q · filed 2014-05-09 | $250.00K 10-Q · filed 2013-05-07 | $530.12K derived: sum of 2 quarters · filed 2014-05-09 | $818.40K derived: sum of 3 quarters · filed 2014-05-09 | $1.03M derived: sum of 4 quarters · filed 2014-05-09 |
| 2012-12-31 | $280.05K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-14 | $568.33K derived: sum of 2 quarters · filed 2014-03-14 | $783.13K derived: sum of 3 quarters · filed 2014-03-14 | $1.02M 10-K · filed 2014-03-14 | |
| 2012-09-30 | $288.28K 10-Q · filed 2013-11-08 | $503.08K derived: sum of 2 quarters · filed 2013-11-08 | $743.95K 10-Q · filed 2013-11-08 | ||
| 2012-06-30 | $214.80K 10-Q · filed 2013-08-07 | $455.67K 10-Q · filed 2013-08-07 | |||
| 2012-03-31 | $241.00K 10-Q · filed 2013-05-07 | ||||
| 2011-12-31 | $730.00K 10-K · filed 2014-03-14 | ||||
| 2011-03-31 | $255.00K derived: 10-K 12 month − 10-K 9 month · filed 2013-03-15 | $1.00M 10-K · filed 2013-03-15 | |||
| 2010-12-31 | $748.00K 10-K · filed 2014-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |